BD PROJECTS
Product for Licensing
Project ID：BP-20240318-OR-029 Product Brief Summary Key Advantages: It demonstrated potent…
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
If your company is interested in the new NMTi payload, please contact DrugTimes BD team as soon as possible!
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
If interested in this asset, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
无法提供摘要。这是一篇受保护的文章。
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
Request for Product
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
Please contact the DrugTimes BD team as soon as possible!
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
If your company is interested in this opportunity, please contact us as soon as possible!
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
If interested, please send an email message to BD@drugtimes.cn, and indicate the project ID in the subject line
Project ID: BP-20240430-L-EE-81 About IBD Inflammatory bowel disease (IBD) is a gro…
Please contact us. Our email address is BD@drugtimes.cn
Bio News
The info will be updated in the coming days
Carefully selected industry hot news! Synchronized push in Chinese and English! Has your c…
Warmest congratulations to Legend Bio and JnJ!
On the morning of August 16, 2024, at 10:00, the Future Science Prize, the first science p…
Congratulations to Lilly and Morphic! This acquisition will expand Lilly’s immunology pipeline with oral integrin therapies
This is an important milestone for China’s innovative drug industry.
Congratulations to Eli Lilly and AD patients!
Warmest congratulations to Eli Lilly and Radionetics Oncology!
Warmest congratulations to Merck and Orion, and to prostate cancer patients!
Congratulations to Alnylam and patients who may benefit from this exciting progress!
Congratulations to Novo Nordisk and diabetes patients!
Congratulations to Gilead Sciences and HIV patients!
Insights
For more reports, please follow DrugTimes. Many thanks!
Drug discovery and development is not easy. We pay respect to all the heroes
For upcoming reports, please follow DrugTimes
Congratulations to Johnson & Johnson!
What will be the fate of this new player in autoimmune diseases in the future?
A Biopharma with outstanding product innovation and internal adjustment capabilities has no reason not to navigate through the cycle
Drug development is not easy, and we pay tribute to the heroes of innovative drug development!
The bright past is worth learning from by R&D personnel of later generations and their role and responsibility is to realize the commercialization of today’s cutting-edge technologies
The development of original new drugs has always been considered a high-risk industry. A d…
Welcome friends to leave a message in the comments section!
DrugTime team will follow up on this key subject. Please stay tuned
DrugTimes will continue to pay attention and report timely
